Volition Targets $36B Market With 99% Pure Cancer DNA Test

Volition Achieves Over 99% Purity in Cancer DNA Isolation

Volition announced a critical breakthrough in its liquid biopsy platform on March 18, 2026, reporting that its technology can now isolate circulating tumor DNA (ctDNA) with greater than 99% purity. This level of precision is a significant step forward in the field of oncology diagnostics, as it enables more sensitive and accurate detection of cancer signals from a simple blood draw. The achievement moves the technology past a key technical hurdle and directly initiates the next phase of its business strategy.

Immediately following the technical validation, Volition confirmed it has entered into active discussions with global diagnostic leaders. The goal of these partnerships is to accelerate the path to commercialization, leveraging the infrastructure and market access of established players. This strategy aims to rapidly integrate Volition's high-purity isolation method into mainstream clinical practice.

Breakthrough Targets $36B Early Detection Market

The company is strategically targeting a combined Total Addressable Market (TAM) estimated at $36 billion. This market is segmented into two primary areas: early-stage cancer detection and Minimal Residual Disease (MRD) testing. MRD testing is used to monitor patients after treatment to detect any remaining cancer cells, which can help guide further therapy and predict recurrence. Volition's ability to provide a highly pure sample of cancer DNA is crucial for both applications, potentially offering a more reliable tool than existing methods.

This technological advance positions Volition to compete in a rapidly growing and valuable segment of healthcare. By addressing the need for non-invasive, accurate, and early cancer screening, the company's platform could disrupt current diagnostic standards and capture a significant share of the multi-billion dollar market.

Rising Cancer Rates in Younger Adults Amplify Market Need

The urgency for better early detection tools is underscored by alarming public health trends. Recent data shows a persistent increase in cancer diagnoses among younger populations, with colorectal cancer rates for those under 50 rising one-to-two percent annually. This has prompted legislative action, such as the proposed Colorectal Cancer Early Detection Act, which aims to fund screening for higher-risk individuals under 45.

This demographic shift and the corresponding governmental focus create a strong tailwind for companies like Volition. The growing awareness and demand for proactive screening, particularly among younger, previously overlooked patient groups, expands the potential user base for new diagnostic technologies. Volition's liquid biopsy offers a less invasive alternative to traditional procedures, making it an attractive option for the broader screening efforts needed to address these rising cancer rates.